5/8/2013

Takeda Pharmaceutical, through Takeda America Holdings, agreed to acquire Inviragen for $35 million in cash plus $215 million in potential milestone fees contingent on the progress of the firm's infectious-disease vaccines. Inviragen is developing vaccines for dengue as well as hand, foot and mouth disease.

Full Story:
The Denver Post

Related Summaries